SG11202110942SA - Sialylated glycoproteins - Google Patents

Sialylated glycoproteins

Info

Publication number
SG11202110942SA
SG11202110942SA SG11202110942SA SG11202110942SA SG11202110942SA SG 11202110942S A SG11202110942S A SG 11202110942SA SG 11202110942S A SG11202110942S A SG 11202110942SA SG 11202110942S A SG11202110942S A SG 11202110942SA SG 11202110942S A SG11202110942S A SG 11202110942SA
Authority
SG
Singapore
Prior art keywords
sialylated glycoproteins
sialylated
glycoproteins
Prior art date
Application number
SG11202110942SA
Inventor
Siddhesh D Patil
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of SG11202110942SA publication Critical patent/SG11202110942SA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591Stabilisation, fragmentation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/40Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41Glycosylation, sialylation, or fucosylation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52Constant or Fc region; Isotype
    • C07K2317/524CH2 domain
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55Fab or Fab'

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
SG11202110942SA 2019-04-18 2020-04-17 Sialylated glycoproteins SG11202110942SA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962836016P 2019-04-18 2019-04-18
PCT/US2020/028863 WO2020215021A1 (en) 2019-04-18 2020-04-17 Sialylated glycoproteins

Publications (1)

Publication Number Publication Date
SG11202110942SA true SG11202110942SA (en) 2021-11-29

Family

ID=72837963

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202110942SA SG11202110942SA (en) 2019-04-18 2020-04-17 Sialylated glycoproteins

Country Status (20)

Country Link
US (1) US20220211849A1 (en)
EP (1) EP3955962A4 (en)
JP (1) JP2022529168A (en)
KR (1) KR20220002963A (en)
CN (1) CN113795275A (en)
AU (1) AU2020259492A1 (en)
BR (1) BR112021020509A8 (en)
CA (1) CA3137101A1 (en)
CL (1) CL2021002668A1 (en)
CO (1) CO2021013926A2 (en)
CR (1) CR20210521A (en)
EA (1) EA202192860A1 (en)
EC (1) ECSP21078309A (en)
IL (1) IL287306A (en)
JO (1) JOP20210281A1 (en)
MX (1) MX2021012710A (en)
PE (1) PE20220383A1 (en)
SG (1) SG11202110942SA (en)
WO (1) WO2020215021A1 (en)
ZA (1) ZA202109184B (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA55033A (en) 2019-02-18 2021-12-29 Lilly Co Eli THERAPEUTIC ANTIBODY FORMULATION
US20230417762A1 (en) 2020-11-20 2023-12-28 Momenta Pharmaceuticals, Inc. Sialylated glycoproteins
US11735303B2 (en) * 2021-06-22 2023-08-22 David Haase Apparatus and method for determining a composition of a replacement therapy treatment

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1832756A (en) * 2003-06-09 2006-09-13 约翰·A·麦金太尔 Method of altering the binding specificity of proteins by oxidation-reduction reactions
EP1532983A1 (en) * 2003-11-18 2005-05-25 ZLB Bioplasma AG Immunoglobulin preparations having increased stability
BRPI0614100A2 (en) * 2005-08-03 2011-03-09 Immunogen Inc liquid immunoconjugate formulations
EP2435474A2 (en) * 2009-05-27 2012-04-04 Baxter International Inc A method to produce a highly concentrated immunoglobulin preparation for subcutaneous use
FR2961107B1 (en) * 2010-06-15 2012-07-27 Lab Francais Du Fractionnement HUMAN IMMUNOGLOBULIN COMPOSITION STABILIZED
WO2014052360A2 (en) * 2012-09-26 2014-04-03 Momenta Pharmaceuticals, Inc. Glycoprotein preparations
WO2014179601A2 (en) * 2013-05-02 2014-11-06 Momenta Pharmaceuticals, Inc. Sialylated glycoproteins
CN105324487B (en) * 2013-05-29 2020-01-17 豪夫迈·罗氏有限公司 Quantitative control of sialylation
JP7177777B2 (en) * 2017-01-11 2022-11-24 セルトリオン, インク. Stable liquid formulation

Also Published As

Publication number Publication date
US20220211849A1 (en) 2022-07-07
WO2020215021A1 (en) 2020-10-22
BR112021020509A8 (en) 2023-01-10
EP3955962A1 (en) 2022-02-23
BR112021020509A2 (en) 2022-03-15
ZA202109184B (en) 2023-04-26
JOP20210281A1 (en) 2023-01-30
CO2021013926A2 (en) 2021-10-29
MX2021012710A (en) 2021-11-12
CL2021002668A1 (en) 2022-05-27
PE20220383A1 (en) 2022-03-18
IL287306A (en) 2021-12-01
JP2022529168A (en) 2022-06-17
EP3955962A4 (en) 2022-12-14
ECSP21078309A (en) 2021-11-30
CA3137101A1 (en) 2020-10-22
CN113795275A (en) 2021-12-14
AU2020259492A1 (en) 2021-11-11
EA202192860A1 (en) 2021-12-23
KR20220002963A (en) 2022-01-07
CR20210521A (en) 2022-04-01

Similar Documents

Publication Publication Date Title
CA190078S (en) Case
GB2597191B (en) Product-display system
CA194649S (en) Shed
ZA202109184B (en) Sialylated glycoproteins
GB202013705D0 (en) No Title- Early Entry
CA188243S (en) Shed
IL286570A (en) System
CA188241S (en) Shed
CA188242S (en) Shed
GB201901489D0 (en) Interfaces between components
EP3924957C0 (en) Cloth-tensioning system
EP3708490C0 (en) Aircraft
EP3914513C0 (en) Aircraft
GB201913411D0 (en) Aircraft system
GB201902531D0 (en) Composite
GB201902778D0 (en) Composite stiffener
GB2584464B (en) Aircraft
GB201911915D0 (en) Aircraft wing-pylon connection
GB2585362B (en) Cabin
GB202020288D0 (en) Face shields
GB2586251B (en) Connection arrangement
CA189431S (en) Case
CA189432S (en) Case
GB201914493D0 (en) Aircraft
GB201901239D0 (en) eVTOL aircraft concept